You are on page 1of 6

Orthomolecular Treatment for Adverse Effects of Human

Papilloma Virus (HPV) Vaccine
by Atsuo Yanagisawa, MD, PhD

(OMNS May 7, 2015) Immunization of adolescent girls with the human papilloma-virus (HPV)
vaccine was initiated with the intention to prevent uterine and cervical cancer. The first HPV
vaccine, called "Gardasil" (Merck) was approved in 2006, and a second vaccine called
"Cervarix" (GSK) was introduced in 2007. By the end of 2013, approximately 130 million
doses of Gardasil and 44 million doses of Cervarix had been distributed worldwide. In 2010,
both vaccines were widely given to Japanese girls. In April 2013, Japan added both HPV
vaccines to their government recommended vaccination schedule.

High incidence of side effects

In June 2013, only 2 months after the law was issued, the Japanese government suspended
the recommendation for these vaccines. A new study reported that the adverse events of
Gardasil and Cervarix were 1.7 to 3.6 times higher than other vaccines. The government task
force analyzed reports of HPV vaccine injuries. They examined 2,500 cases and found 617
(25%) cases to be "serious."

Amazingly, the official task force then issued this statement:

"We find no physical cause for the alleged and presumed adverse reactions in those
vaccinated girls, so we cannot recommend any specific therapy. We conclude that their so-
called adverse reactions are psychosomatic. The government should provide counseling to
the girls so that they may be freed from their psychosomatic reactions."

Severity of side effects

When other health experts re-evaluated those cases, they determined 1,112 (44%) to be
serious. The initial onset of symptoms occurred several weeks to a year after the HPV vaccine
was given. They included: headache, dizziness, muscle weakness and pain, nausea,
hypersomnia, learning difficulty, impaired writing, photophobia, tremors of arms, feet and
fingers, joint pain, irregular menstruation, gait disturbance, memory loss, skin eczema and

Girls who had adverse effects from the HPV vaccine were variously diagnosed with:

1. Higher brain dysfunction
2. Guillain-Barré syndrome
3. Multiple sclerosis
4. ADEM: acute disseminated encephalomyelitis
5. SSPE: subacute sclerosing panencephalitis
6. CRPS: Complex regional pain syndrome
7. POTS: Postural orthostatic tachycardia syndrome
8. Anti-phospholipid antibody syndrome
9. SLE: systemic lupus erythematosus
10. Rheumatoid arthritis
11. Chronic fatigue syndrome
12. Fibromyalgia
13. Cushing's syndrome (exposure to high level of cortisol)
14. Hashimoto's disease (immune system attacks the thyroid)
15. Hyperprolactinemia (high prolactin, induces breast development and lactation)

Laboratory findings included:

1. Normal blood chemistry
2. No inflammatory finding in the blood
3. Increased pro-inflammatory cytokines in the spinal fluid (IL-2, IL-10, TNF-à)
4. Reduced brain blood flow by perfusion scintigraphy
5. High leukocyte sensitivity against aluminum.

HPV vaccine contains toxic aluminum

Vaccines often contain an adjuvant, which is an additional chemical added to provoke the
body's immune response to the vaccine. The HPV vaccines contained an adjuvant that
consisted of an aluminum compound, amorphous aluminum hydroxyphosphate sulfate

Current research strongly implicates aluminum adjuvants in various inflammatory neurological
and autoimmune disorders in both humans and animals. For example, a recent research
paper explained that nanomaterials such as this aluminum adjuvant can be transported by
immune system cells first into the blood, lymph nodes, and spleen, and in some cases may
penetrate into the brain. [1] This type of access throughout the body is potentially life-
threatening. The brain symptoms are often the most delayed because of the time the
aluminum takes to travel from the blood through the blood-brain-barrier into the brain.

Aluminum accumulates in neurons in the brain, and it is toxic to neurons, causing a variety of
pathological conditions. It inhibits uptake of dopamine and serotonin, which are important
neurotransmitters in the brain. Aluminum toxicity is a known factor in Alzheimer's disease, and
may contribute symptoms of Parkinson's disease. Dementia resulting from kidney dialysis is
related to aluminum and results in memory loss, loss of coordination, confusion and
disorientation. In animal experiments, rabbits given aluminum showed difficulty in memory
retention and difficulty in learning.
Effective treatments for the adverse reactions from the HPV vaccine

Protocol 1:
Vitamin C, Glutathione Cocktail, given by I.V. (Dr. Yanagisawa)

Sterile water, 250ml
Vitamin C, 12.5g - 25g (12,500 - 25,000 mg)
Glutathione, 800 - 1,200mg
0.5 M Magnesium sulfate, 10-20ml
8.5% Calcium gluconate, 2ml
Vitamin B-complex (B1, B2, B3, B5, B6, B12)

Case History: 17yrs, female.

May 23, 2014. When she visited the clinic, she could not walk without assistant. She
complained of general fatigue, joint pain and frequent involuntary movement. The patient
was treated with intravenous Myers' cocktail containing VCG (vitamin C 12.5g and
glutathione 1200mg) and oral nutritious supplements (vitamin C, vitamin B, curcumin,
SAMe, etc). After 10 days of vitamin C and Glutathione therapy, she could walk without an
assistant. By December 2014, she could play tennis. Frequency and duration of
involuntary movements were decreased and fatigue and pain dramatically decreased.

Protocol 2:
Vitamin C, Glutathione & EDTA, given by I.V. (Dr. Claus Hancke, Denmark)

5% Glucose, 250ml
Vitamin C (500mg/ml), 50ml (25,000mg)
Na2-EDTA (150mg/ml), 10ml (1.5g)
8.4% Na Bicarbonate, 10ml
MgSO4 (2mmol/ml), 4ml
When the infusion almost done, add Glutathione 150mg/ml, 4ml (600 mg)

Protocol 3:
Phospholipid Exchange Therapy and Glutathione, given I.V. (Dr. Damien Downing, UK)

This membrane stabilizing protocol is a closely-monitored version of the lipid rescue that
anesthetists use in toxic emergencies. As with all IV treatments, this should only be done
by someone with full training.

Phosphatidylcholine (as Intralipid or Essentiale only) 1,250mg plus
Leucovorin (folinic acid) 10mg plus
Glutathione 1,000mg plus
Protocol 4:
Oral supplements (Dr. Claus Hancke and Dr. Atsuo Yanagisawa)

2, 3x per day (Increased slowly from 1/day
Multiple vitamin/mineral
to 6/day).
EPA/DHA/GLA 2 x 3 doses per day
Vitamin D, (1500 IU) 1x3
Magnesium citrate 1x2
Vitamin C, 750mg 2x2
B-complex 1x2
Thiamine (B1), 300mg 1x1
Probiotic 1x2
Turmeric 1x2
Lipoic acid, 300mg 1x2
CoQ10, 100mg 1x1
S-adenosylmethionine (SAMe) 400mg/day
MTHF 5- methyltetrahydrofolate (MTHF) 5mg/day

Protocol 5:
Dietary principles (Dr. Claus Hancke)

Alkaline foods with no fish, sugar, wheat or milk.
No chemicals or aluminum in the food (e.g. aluminum in table salt)
More greens, nuts and berries.
Use healthy fats: olive oil, coconut oil and organic butter.
Choose tea rather than coffee.
No alcohol or tobacco.

To make the body more alkaline, take a glass of water with a teaspoon bicarbonate and
the juice from a lemon 3 or 4 times a day.

Other treatment options:

1. Ferulic acid from rice bran for memory loss, learning disturbance
2. Low-dose theophylline for headache, 50-100mg in the morning (excellent
improvement in some patients)
3. Low-dose naltrexone (LDN) for hypersomnia, headache, 3mg before sleep
4. Supplements for joint pain, gait disturbance, and to improve stem cell release.

The timing and appearance of adverse effects and symptoms of the HPV vaccines vary for
each patient. These symptoms differ from anything that we have previously experienced.
Unfortunately, governments and medical professions have not faced the problem proactively.
Although treatment with orthomolecular medicine has been helpful in many cases, it is not
always adequate to return the patient to normal. In order to establish an effective protocol,
scientists and clinicians must work together.

The onset of adverse effects from HPV vaccines arrives several months to a year or more
after the injection. This delay makes it very difficult to link the symptoms with the HPV vaccine.
In Japan, more than 1,200 girls have been registered as "severe cases" and more patients are
registered every day. We estimate more than 100,000 unrecognized cases of mild to
moderate adverse effects in girls vaccinated with HPV. The symptoms are commonly seen as
fatigue, muscle pain, headache, learning disturbance, difficulty in awakening, hypersomnia,
irregular menstruation, among others.

Doctors should be made aware of HPV vaccine adverse effects. Unfortunately, there is no
evidence about the effectiveness of cervical cancer prevention by the HPV vaccines.
Therefore, in my opinion as a concerned physician, we should discontinue this harmful HPV
vaccine as soon as possible.


I would like to thank Dr. Damien Downing, president of the British Society for Ecological
Medicine, and Dr. Claus Hancke, FACAM, specialist in general medicine, for their very
important contributions to this paper.

(Dr. Atsuo Yanagisawa is president of the Japanese College of Intravenous Therapy.
Previously he was Professor of Clinical Medicine at the Kyorin University School of Health
Sciences, and Professor of Clinical Cardiology at Kyorin University Hospital. Dr. Yanagisawa
is the author of 140 scientific papers in English and Japanese and has published several
books. This OMNS is a condensed version of Dr. Yanagisawa's presentation at the 2015
Orthomolecular Medicine Today conference in Toronto, Canada )


1. Khan Z, Combadière C, Authier F-J et al. Slow CCL2-dependent translocation of
biopersistent particles from muscle to brain. BMC Medicine 2013, 11:99. DOI: 10.1186/1741-
Video providing case history:

Nutritional Medicine is Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness.

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-
commercial informational resource.

Editorial Review Board:

Ian Brighthope, M.D. (Australia)
Ralph K. Campbell, M.D. (USA)
Carolyn Dean, M.D., N.D. (USA)
Damien Downing, M.D. (United Kingdom)
Michael Ellis, M.D. (Australia)
Martin P. Gallagher, M.D., D.C. (USA)
Michael Gonzalez, D.Sc., Ph.D. (Puerto Rico)
William B. Grant, Ph.D. (USA)
Michael Janson, M.D. (USA)
Robert E. Jenkins, D.C. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Peter H. Lauda, M.D. (Austria)
Thomas Levy, M.D., J.D. (USA)
Stuart Lindsey, Pharm.D. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Erik Paterson, M.D. (Canada)
W. Todd Penberthy, Ph.D. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Robert G. Smith, Ph.D. (USA)
Jagan Nathan Vamanan, M.D. (India)
Atsuo Yanagisawa, M.D., Ph.D. (Japan)

Andrew W. Saul, Ph.D. (USA), Editor and contact person. This is a comments-only address; OMNS is unable to
respond to individual reader emails. However, readers are encouraged to write in with their
viewpoints. Reader comments become the property of OMNS and may or may not be used for